Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Xenetic Biosciences, Inc. (XBIO)
:XBIO
Holding XBIO?
Track your performance easily
XBIO Stock Chart & Stats
Day’s Range― - ―
52-Week Range$2.78 - $5.20
Previous CloseN/A
Volume4.73K
Average Volume (3M)13.07K
Market Cap
$6.56M
Enterprise Value-$177.52K
Total Cash (Recent Filing)$4.05M
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
Beta1.09
Next Earnings
May 08, 2025EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.65
Shares Outstanding1,542,139
10 Day Avg. Volume8,286
30 Day Avg. Volume13,072
Standard Deviation0.31
R-Squared0.15
Alpha-0.01
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)3.64
Price to Cash Flow (P/CF)-3.60
P/FCF Ratio0.00
Enterprise Value/Market Cap-0.03
Enterprise Value/Revenue-0.07
Enterprise Value/Gross Profit-0.07
Enterprise Value/Ebitda0.04
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusHold
Number of Analyst Covering1
Xenetic Biosciences News
PremiumCompany Announcements
Xenetic Biosciences Expands Collaboration for Cancer Treatment
Ownership Overview
―
Insiders
1.38% Mutual Funds
0.18% Other Institutional Investors
97.81% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
XBIO FAQ
What was Xenetic Biosciences, Inc.’s price range in the past 12 months?
Xenetic Biosciences, Inc. lowest stock price was $2.78 and its highest was $5.20 in the past 12 months.
What is Xenetic Biosciences, Inc.’s market cap?
Xenetic Biosciences, Inc.’s market cap is $6.56M.
When is Xenetic Biosciences, Inc.’s upcoming earnings report date?
Xenetic Biosciences, Inc.’s upcoming earnings report date is May 08, 2025 which is in 107 days.
How were Xenetic Biosciences, Inc.’s earnings last quarter?
Xenetic Biosciences, Inc. released its earnings results on Nov 13, 2024. The company reported -$0.28 earnings per share for the quarter, missing the consensus estimate of -$0.14 by -$0.14.
Is Xenetic Biosciences, Inc. overvalued?
According to Wall Street analysts Xenetic Biosciences, Inc.’s price is currently Overvalued.
Does Xenetic Biosciences, Inc. pay dividends?
Xenetic Biosciences, Inc. does not currently pay dividends.
What is Xenetic Biosciences, Inc.’s EPS estimate?
Xenetic Biosciences, Inc.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Xenetic Biosciences, Inc. have?
Xenetic Biosciences, Inc. has 1,542,139 shares outstanding.
What happened to Xenetic Biosciences, Inc.’s price movement after its last earnings report?
Xenetic Biosciences, Inc. reported an EPS of -$0.28 in its last earnings report, missing expectations of -$0.14. Following the earnings report the stock price went down -11.622%.
Which hedge fund is a major shareholder of Xenetic Biosciences, Inc.?
Currently, no hedge funds are holding shares in XBIO
---
Company Description
Xenetic Biosciences, Inc.
Xenetic Biosciences, Inc. is a biopharmaceutical company, which focuses on progressing XCART, a personalized CAR T platform technology engineered to target patient-specific tumor neoantigens. The company is initially advancing cell-based therapeutics targeting the unique B-cell receptor on the surface of an individual patient's malignant tumor cells for the treatment of B-cell lymphomas. The XCART has the potential to fuel a robust pipeline of therapeutic assets targeting oncology indications. Additionally, Xenetic is leveraging PolyXen, its proprietary drug delivery platform, by partnering with biotechnology and pharmaceutical companies. The PolyXen has demonstrated its ability to improve the half-life and other pharmacological properties of next-generation biologic drugs. Xenetic Biosciences was founded on and is headquartered in Framingham, MA.
---
Technical Analysis
Atossa Therapeutics
―
Cyclacel Pharmaceuticals
―
Ibio
―
Curis
―
Genprex
―
Aurinia Pharmaceuticals
―
---